SCHEMBL1159802

SCHEMBL1159802

O=c1[nH]ccc2cc(Nc3ccccn3)nc(N3CCCC3)c12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.39
JAK2 O60674 1/20 0.39
APAF1 O14727 1/20 0.39
TDP2 O95551 1/20 0.39
CDC25B P30305 1/20 0.39
CASP6 P55212 1/20 0.39
RCE1 Q9Y256 1/20 0.39
BTK Q06187 1/20 0.38
GRM5 P41594 1/20 0.38
ZAP70 P43403 4/20 0.38
TYK2 P29597 1/20 0.38
BPTF Q12830 1/20 0.37
LRRK2 Q5S007 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
ADORA2A P29274 1/20 0.35
MAP3K12 Q12852 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1159997 0.90 ZAP70 (0.48) EGFRZAP70LRRK2
SCHEMBL6526413 0.85 MAP3K12 (0.47) JAK2ZAP70TYK2MAPK8MAPK9
SCHEMBL1158642 0.76 FER (0.46) JAK2APAF1TDP2CDC25BCASP6
SCHEMBL1158395 0.76 ZAP70 (0.47) ZAP70LRRK2MAP3K12
SCHEMBL1158500 0.76 FER (0.43) JAK2APAF1TDP2CDC25BCASP6
SCHEMBL1158385 0.75 ZAP70 (0.68) EGFRJAK2ZAP70MAPK10
SCHEMBL1158836 0.73 JAK2 (0.40) JAK2APAF1TDP2CDC25BCASP6
SCHEMBL1158115 0.72 JAK2 (0.43) EGFRJAK2APAF1TDP2CDC25B
SCHEMBL1158539 0.72 ZAP70 (0.37) JAK2APAF1TDP2CDC25BCASP6
SCHEMBL6519945 0.72 JAK2 (0.48) JAK2APAF1TDP2CDC25BCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN EGFR 1168/4885JAK2 19/4885APAF1 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.